logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9624174 B1

PDFFull Text
Date of Patent:
Apr. 18, 2017

Filed:

Nov. 17, 2015

Compounds as diacylglycerol acyltransferase inhibitors

Applicant:

Glaxosmithkline Llc, Wilmington, New Castle, DE (US);

Inventors:

Mui Cheung, King of Prussia, PA (US);

Raghuram S. Tangirala, Secunderabad, IN;

Assignee:

GlaxoSmithKline LLC, Wilmington,New Castle, DE (US);

Attorneys:

Duke M. Fitch

Kathryn A. Lutomski

Edward R. Gimmi

Primary Examiner:

Jeffrey H Murray

Int. Cl.
CPC ...
A61K 31/50 (2006.01); A61K 31/501 (2006.01); A61K 31/4965 (2006.01); A01N 43/40 (2006.01); A61K 31/44 (2006.01); A01N 43/78 (2006.01); A61K 31/425 (2006.01); C07D 401/00 (2006.01); C07D 403/00 (2006.01); C07D 405/00 (2006.01); C07D 409/00 (2006.01); C07D 411/00 (2006.01); C07D 413/00 (2006.01); C07D 417/00 (2006.01); C07D 419/00 (2006.01); C07D 213/04 (2006.01); C07D 277/00 (2006.01); C07D 213/72 (2006.01); A61K 31/122 (2006.01); C07D 237/20 (2006.01); C07D 213/74 (2006.01); C07D 277/42 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 213/72 (2013.01); A61K 31/122 (2013.01); A61K 31/50 (2013.01); C07D 213/74 (2013.01); C07D 237/20 (2013.01); C07D 277/42 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01);
Abstract

Compounds of Formula (I) are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), useful in the treatment of obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.

Find Patent Forward Citations

Loading…